


## LABORATORY CONFIRMED COVID 19 PATIENT



### EUA/ Off label therapies (use based on limited available evidence):

- Remdesivir (EUA)** to be considered in Moderate to severe disease (requiring oxygen): Rule out renal or hepatic dysfunction (eGFR <30 ml/min/m<sup>2</sup>; AST/ALT >5 times ULN), Not to be combined with HCQ
- Tocilizumab (Off-label)** may be considered in when all the below criteria are met: Moderate to Severe disease, significantly raised inflammatory markers (CRP &/or IL-6), Not improving despite use of steroids, Rule out active bacterial infections. The recommended dose is 4 to 8mg/kg (with a maximum dose of 800 mg at one time) in 100 ml NS over 1 hour (dose can be repeated once after 12 to 24 hours, if needed)
- Convalescent plasma (Off-label)** may be considered when following are met: Early moderate disease, Increasing oxygen requirement
- Ivermectin** Clinical trial is going on. Physicians should share clinical records and data regarding use of Ivermectin with state. **Ivermectin** and **doxycycline** combination can be used in mild-moderate diseases.